A survey of the signaling pathways involved in megakaryocytic differentiation of the human K562 leukemia cell line by molecular and c-DNA array analysis

被引:71
作者
Jacquel, A
Herrant, M
Defamie, V
Belhacene, N
Colosetti, P
Marchetti, S
Legros, L
Deckert, M
Mari, B
Cassuto, JP
Hofman, P
Auberger, P
机构
[1] Univ Nice Sophia Antipolis, U526, Fac Med Pasteur, INSERM,Equipe Labellisee Ligue Natl Canc,IFR50, F-06107 Nice 2, France
[2] CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France
[3] Hop Archet, Hematol Serv, F-06202 Nice 2, France
[4] Hop Archet, INSERM, U576, F-06202 Nice, France
[5] Univ Nice Sophia Antipolis, INSERM, U721, IFR50,Fac Med, F-06107 Nice 2, France
关键词
megakaryocyte differentiation; PKC; MAPK; c-DNA array; leukemia;
D O I
10.1038/sj.onc.1209119
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The K562 cell line serves as a model to study the molecular mechanisms associated with leukemia differentiation. We show here that cotreatment of K562 cells with PMA and low doses of SB202190 (SB), an inhibitor of the p38 MAPK pathway, induced a majority of cells to differentiate towards the megakaryocytic lineage. Electronic microscopy analysis showed that K562 cells treated with PMA+SB exhibited characteristic features of physiological megakaryocytic differentiation including the presence of vacuoles and demarcation membranes. Differentiation was also accompanied by a net increase in megakaryocytic markers and a reduction of erythroid markers, especially when both effectors were present. PMA effect was selectively mediated by new PKC isoforms. Differentiation of K562 cells by the combination of PMA and SB required Erk1/2 activation, a threshold of JNK activation and p38 MAPK inhibit ion. Interestingly, higher concentrations of SB, which drastically activated JNK, blocked megakaryocytic differentiation, and considerably increased cell death in the presence of PMA. c-DNA microarray membranes and PCR analysis allow us to identify a set of genes modulated during PMA-induced K562 cell differentiation. Several gene families identified in our screening, including ephrins receptors and some angiogenic factors, had never been reported so far to be regulated during megakaryocytic differentiation.
引用
收藏
页码:781 / 794
页数:14
相关论文
共 47 条
[1]   INDUCED-DIFFERENTIATION OF K562 LEUKEMIA-CELLS - A MODEL FOR STUDIES OF GENE-EXPRESSION IN EARLY MEGAKARYOBLASTS [J].
ALITALO, R .
LEUKEMIA RESEARCH, 1990, 14 (06) :501-&
[2]  
Belhacène N, 1998, FASEB J, V12, P531
[3]   Protein kinase C θ and ε promote T-cell survival by a rsk-dependent phosphorylation and inactivation of BAD [J].
Bertolotto, C ;
Maulon, L ;
Filippa, N ;
Baier, G ;
Auberger, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (47) :37246-37250
[4]   Eph receptor tyrosine kinases in tumor and tumor microenvironment [J].
Brantley-Sieders, D ;
Schmidt, S ;
Parker, M ;
Chen, J .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (27) :3431-3442
[5]   Blocking NF-κB activation in Jurkat leukemic T cells converts the survival agent and tumor promoter PMA into an apoptotic effector [J].
Busuttil, V ;
Bottero, V ;
Frelin, C ;
Imbert, V ;
Ricci, JE ;
Auberger, P ;
Peyron, JF .
ONCOGENE, 2002, 21 (20) :3213-3224
[6]   The p38 pathway provides negative feedback for Ras proliferative signaling [J].
Chen, G ;
Hitomi, M ;
Han, JH ;
Stacey, DW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (50) :38973-38980
[7]  
CHENG T, 1994, J BIOL CHEM, V269, P30848
[8]   Ultrastructure of platelet formation by human megakaryocytes cultured with the Mpl ligand [J].
Cramer, EM ;
Norol, F ;
Guichard, J ;
BretonGorius, J ;
Vainchenker, W ;
Masse, JM ;
Debili, N .
BLOOD, 1997, 89 (07) :2336-2346
[9]   Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl+ K562 leukemic cells by Gab2 [J].
Dorsey, JF ;
Cunnick, JM ;
Mane, SM ;
Wu, J .
BLOOD, 2002, 99 (04) :1388-1397
[10]   IEX-1: a new ERK substrate involved in both ERK survival activity and ERK activation [J].
Garcia, J ;
Ye, YB ;
Arranz, V ;
Letourneux, C ;
Pezeron, G ;
Porteu, F .
EMBO JOURNAL, 2002, 21 (19) :5151-5163